A5040417184- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Polyomavirus and related diseases
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Childhood Cancer Survivors' Quality of Life
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Mesenchymal stem cell research
- Cytomegalovirus and herpesvirus research
- Systemic Sclerosis and Related Diseases
- Immunodeficiency and Autoimmune Disorders
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Hemoglobinopathies and Related Disorders
- RNA Interference and Gene Delivery
- Inflammatory Bowel Disease
- Blood disorders and treatments
Inserm
2016-2025
Hôpital Saint-Antoine
2016-2025
Sorbonne Université
2016-2025
European Society for Blood and Marrow Transplantation
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Centre de Recherche Saint-Antoine
2016-2025
Acute Leukemia French Association
2014-2023
Sapienza University of Rome
1996-2023
Aristotle University of Thessaloniki
2023
Hospital of Southern Norway
2023
Promising results of cord-blood transplants from unrelated donors have been reported in adults.We compared outcomes 682 adults with acute leukemia who received a hematopoietic stem-cell transplant an donor: 98 cord blood and 584 bone marrow. The transplantations were performed 1998 through 2002 to Eurocord the European Blood Marrow Transplant Group.Recipients younger than recipients marrow (median, 24.5 vs. 32 years age; P<0.001), weighed less 58 68 kg; had more advanced disease at time...
To evaluate the role of donor lymphocyte infusion (DLI) in treatment relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT).We retrospectively analyzed data 399 patients with AML first hematological relapse HSCT whose did (n = 171) or not 228) include DLI. After correction for imbalances and established risk factors, two groups were compared respect to overall survival. Further, a detailed analysis factors survival among DLI recipients was...
Background Autologous hematopoietic stem cell transplantation has been used since 1996 for the treatment of severe autoimmune diseases refractory to approved therapies. We evaluated long-term outcomes these transplants and aimed identify potential prognostic factors.Design Methods In this observational study we analyzed all first autologous reported European Group Blood Marrow Transplantation (EBMT) registry between 1996–2007. The primary end-points analysis were overall survival,...
Purpose Reduced intensity conditioning regimen (RIC) is increasingly used in hematopoietic stem cell transplantation (HSCT). Unrelated donor (UD) transplants have more complications. We wanted to examine if RIC a valid treatment option using UD acute myeloblastic leukemia (AML). Patients and Methods Between 1999 2005, 401 patients with AML were treated 1,154 received myeloablative (MAC), reported the European Group for Blood Marrow Transplantation Registry. < ≥ 50 years of age analyzed...
Purpose Patients with acute myeloid leukemia (AML) and FLT3/internal tandem duplication (FLT3/ITD) have poor prognosis if treated chemotherapy only. Whether this alteration also affects outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) remains uncertain. Methods We analyzed 206 patients who underwent HLA-identical sibling matched unrelated HSCTs reported to the European Group for Blood Marrow Transplantation a diagnosis of AML normal cytogenetics data on FLT3/ITD...
These updated EBMT guidelines review the clinical evidence, registry activity and mechanisms of action haematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) other immune-mediated neurological diseases provide recommendations for patient selection, transplant technique, follow-up future development. The major focus is on autologous HSCT (aHSCT), used MS over two decades currently fastest growing indication this treatment Europe, with increasing evidence to support its use...
Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from matched sibling donors (MSD) or unrelated (UD) is limited and with controversial results. The study aim was to evaluate PT-Cy GVHD post-HSCT MSD UD transplants. We analyzed 423 patients acute leukemia who received alone combination other immunosuppressive (IS) drugs prophylaxis. Seventy-eight (group 1); 204 one IS drug—cyclosporine-A...